Provided are a compound as represented by structural formula (I)({5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-6-aminopyridazin-3-yl}-N-{4-[((3S,5R)-3,5-dimethylpiperazinyl)carbonyl]phenyl}carboxamide hydrochloride) and a novelcrystalline formof a hydrate or solvate of the compound. Further provided are a manufacturingmethod of thecompound and crystalline form, a related intermediate, a pharmaceuticalcompositioncomprising the compound, an application using the compound or the crystallineform forpreparing a pharmaceutical product for treating a disease, symptom, ordisorder, and atherapeutic method for treating a disease, symptom, or disorder.(see formula I)
